Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
haploidentical natural killer cells + nogapendekin alfa inbakicept
- Development stage
- Unknown
- Lead developer
- Altor BioScience
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
This experimental combination therapy is being investigated by the University of Minnesota for the treatment of HIV infection. It involves the adoptive transfer of HLA-haploidentical natural killer (NK) cells that have been activated with nogapendekin alfa inbakicept (N-803). Nogapendekin alfa inbakicept is a recombinant interleukin-15 (IL-15) superagonist protein complex consisting of an IL-15 mutant (IL-15N72D) bound to an IL-15 receptor α/IgG1 Fc fusion protein. The therapeutic strategy utilizes N-803 to enhance the proliferation and cytotoxic activity of the donor NK cells, which are then infused into HIV-infected individuals on stable antiretroviral therapy (ART). The primary goal of this Phase 1 pilot study is to evaluate the safety of the approach and its potential impact on reducing the latent viral reservoir.
- Brand names
- Anktiva
- Other names
- IL-15 superagonistIL15 superagonistIL 15 superagonistIL-15N72D:IL-15RαSu/Fc complex
02
Targets
IL15RA (Interleukin-15 receptor subunit alpha)IL2RB (IL-2 receptor beta chain)
Beyond the preview
Go deeper on haploidentical natural killer cells + nogapendekin alfa inbakicept.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on haploidentical natural killer cells + nogapendekin alfa inbakicept.